Stem cell growth factor (SCGF) is a novel cytokine for primitive hematopoietic progenitor cells. Although it has burst-promoting activity and granulocyte/macrophage colony-promoting activity in vitro, its significance in hematopoiesis in vivo has not been elucidated. In this study, we have established enzyme-linked immunosorbent assay (ELISA) to quantify human SCGF and measured serum cytokines in normal volunteers and 27 patients undergoing stem cell transplantation (SCT), including six autologous and 21 allogeneic transplants. SCGF levels gradually increased after SCT regardless of graft-versushost disease or type of transplant. The maximum level of SCGF was observed during the rapid granulocyte recovery phase in patients subjected to an autologous transplantation, and during the granulocyte stabilization phase in allogeneic patients. SCGF levels in PBSCT patients began to rise earlier than in BMT patients. Two patients with no increment of SCGF after SCT showed delayed engraftment. The source of SCGF was further analyzed by RT-PCR and we found that SCGF was highly expressed in bone marrow (BM) CD34 We have previously identified a novel hematopoietic growth factor, the stem cell growth factor (SCGF). 1 It was detected in the cultured supernatant of KPB-M15 cells, a human myeloid cell line established from a patient with chronic myeloid leukemia in blast crisis. 2 The cDNA for SCGF encodes a 29-kDa polypeptide without N-linked glycosylation, which belongs to the C-type lectin superfamily. Its gene is located on chromosome 19 at position q13.3, where genes for early-acting hematopoietic growth factors of the flk-2/flt3 ligand and interleukin-11 are clustered in humans. SCGF was shown to be expressed in bone and bone marrow (BM) by whole body in situ hybridization. 3 Although SCGF alone does not exhibit colony-stimulating activity, it does have a burst-promoting activity (BPA) and a granulocyte/macrophage (GM) colony-promoting activity (GPA) on erythroid and GM progenitor cells (BFU-E and CFU-GM) in a primary semisolid clonal culture in combination with erythropoietin (Epo) and GM colony-stimulating factor (GM-CSF), respectively, as well as a CFU-GM-supporting activity during short-term liquid culture of BM cells. However, the significance of SCGF in human hematopoiesis in vivo has not been fully elucidated.
Stem cell transplantation (SCT) provides an opportunity to trace the process of hematopoietic reconstitution in vivo, as stem cells given to a recipient following myeloablative therapy proliferate and differentiate until stable hematopoiesis is achieved. 4 Many cytokines are known to control this process of hematopoiesis positively or negatively in vivo. 5 Although there have been a great deal of descriptions about serum cytokine levels following SCT, none of them directly reflects post transplant hematopoiesis. Serum cytokine levels can be affected by the administration of exogenous cytokines such as granulocyte colony-stimulating factor (G-CSF) and also correlate with transplant-related toxicity and graft-versus-host disease (GVHD), which has been demonstrated with interleukin-6 (IL-6). 6, 7 As for other cytokines, serum stem cell factor (SCF) levels, for example, have shown no correlation with post-transplant engraftment, 8 and thrombopoietin (TPO) has a negative correlation with platelet counts and is affected by platelet transfusions. 9, 10 To monitor serum SCGF in the various settings of hematopoiesis in vivo, we have established an enzymelinked immunosorbent assay (ELISA) to quantify human SCGF. Serum concentrations of SCGF, as well as those of SCF, TPO and IL-6, were measured in patients undergoing SCT. We found that the serum SCGF level significantly increased after SCT with or without GVHD and reflected hematopoiesis following SCT, so that it can serve as an indicator of hematopoietic recovery following SCT. By using RT-PCR analysis of SCGF gene expression, the major sources of serum SCGF were supposed to be both CD34 + and CD34 À CD33 + BM mononuclear cells, but not CD34 À CD33 À cells, BM stromal cells or peripheral blood cells. This finding provides clinical evidence for serum SCGF as an indicator of hematopoietic recovery after SCT.
Materials and methods

Generation of monoclonal antibodies against human SCGF
Monoclonal antibodies (MoAbs) against human SCGF were raised using the synthesized peptide, REWEGGWG GAQEEEREREAL (human SCGF (6-26)), and recombinant human SCGF as the immunogen. Five week-old female SD rats (SLC, Shizuoka, Japan) were immunized by i.p. injection of 100 mg of the peptide coupled to keyhole limpet hemocyanin (KLH; Carbiochem, San Diego, CA), with 2 mg of aluminum gel and 10 9 cells of Bordetella pertussis (Serum Institute, Chiba, Japan) as adjuvant, per animal. Six-week-old female Balb/c mice (CLEA Co., Tokyo, Japan) were immunized by i.p. injection of 50 mg of the recombinant human SCGF per animal with the same adjuvant used for the synthesized peptide. The animals were killed 3 or 4 days after the last injection. The spleen cells were fused with P3.X63/Ag8.U1 (P3.U1), at a 10:1 ratio of spleen cells to P3.U1 cells, in PEG 1000 by the method of Kohler and Milstein 11 with some modifications. The antibody activity in the cultured supernatants from each well of the hybridoma was tested by binding ELISA. Positive wells were subcloned twice by the limiting dilution method. We finally obtained two MoAbs, designated as KM2142 and KM2804. KM2142 was raised against the synthesized peptide, and the other was against the recombinant human SCGF. Both MoAbs, KM2142 and KM2804, reacted specifically with the recombinant human SCGF (Figure 1a,b) .
Enzyme immunoassay for detection of SCGF
A sandwich EIA for plasma Ox-LDL was done with a 96-well microtiter plate as the solid phase, with KM2142 antibody as the capture antibody, with biotinylated KM2804 as the second antibody and avidin-alkaline phosphatase as the indicator enzyme. Figure 1c is a typical calibration curve generated by plotting the absorbance at 415 nm vs the logarithm of the concentration of each calibrator.
Performance of ELISA
Serum samples serially diluted gave results close to linearity, indicating that the assay was quantitative and confirming parallelism between the standard and plasma samples.
Serum samples containing low (18.2 ng/ml), medium (58.2 ng/ml) and high (130.5 ng/ml) SCGF were supplemented with potentially interfering agents at various concentrations. There was no substantial interference from lipid up to 5 g/l (in terms of TG), from hemoglobin up to 5 g/l, from direct and indirect bilirubin up to 200 mg/l.
The working range of the assay was established by calculating the coefficient of variation (CV) of each calibrator in five independent calibration curves. The CV obtained for each calibrator from 2.7 to 175.0 ng/ml was o10%.
The assay variation in the present EIA was examined using serum samples that contained SCGF at three different levels (18.2 ng/ml, 58.2 and 130.5 ng/ml). The CVs within assay and between assay were 1.6-2.5% (n ¼ 10) and 2.2-6.3 % (n ¼ 5), respectively. To determine the analytical recovery, SCGF (19.8 and 98.0 ng/ml) was mixed with the serum samples containing 19.4 and 72.8 ng/ ml SCGF (1:9). Recoveries of SCGF ranged from 95.7 to 109.7% (19.4 ng/ml) and from 98.2 to 100.8% (72.8 ng/ml), respectively.
Patients
The subjects were 27 patients who underwent SCT from January 1997 to July 2001 in our institution. In all, 21 patients received allogeneic SCT, while the remaining six received autologous SCT, 14 of the patients who received allogeneic SCT developed acute GVHD. Patient characteristics, type of transplant, conditioning regimen, recovery of BM and GVHD are given in detail in Table 1 . The status of the disease at SCT was complete remission in all patients.
No relapse was observed during the study period. The median time from BMT to absolute neutrophil count (ANC) 4500, platelet count 450 000 and duration of using G-CSF were 11, 14.5 and 13 days for autologous SCT patients. Those of the patients with and without GVHD were 16, 24.5, 22 and 14, 21 and 15, respectively. Acute GVHD was clinically diagnosed using the criteria described by Glucksberg et al.
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Measurement of cytokines
All cytokines were measured by ELISA at four time points as Takatsuka et al. 13 previously described.
(1) before SCT; (2) during the aplastic phase after SCT (day 1-7); (3) during the rapid granulocyte recovery phase (days 8-21 in allogeneic SCT patients and days 9-17 in autologous patients); and (4) at the time of granulocyte stabilization after discontinuation of G-CSF (days 20-40 in allogeneic SCT patients and days 15-27 in autologous patients).
Serum SCF, TPO and IL-6 levels were measured in duplicate using ELISA kits (human SCF and TPO ELISA kits; R&D Systems, Minneapolis, MN, USA and human IL-6 ELISA kit; BioSource International, Camarillo, CA, USA). Minimum detectable levels of SCF, TPO and IL-6 were 31.2, 31.2 and 15.6 pg/ml, respectively.
Statistical analysis
All results are expressed as mean value plus or minus s.d.'s. The paired or unpaired Student's t-test was used to G-CSF=granulocyte colony stimulating factor; BMT=bone marrow transplantation; ANC=absolute neutrophil count; Plt=platelets; GVHD=graft-versus-host disease; NHL=non-Hodgkin's lymphoma; CML=chronic myelocytic leukemia; SAA=severe aplastic anemia; ALL=acute lymohicytic leukemia; AML=acute myelocytic leukemia; MDS=myelodysplastic syndrome; sPBSCT=peripheral blood stem cell transplantation from sibling; uBMT=unrelated BM transplantation; sBMT=BM transplantation from sibling; TBI=total body irradiation; V P-16=etoposide; CY=cyclopho-sphamide; TAI=thoracoabdominal irradiation; Ara-C=cytarabine; MCNU=ranimustine; CBDCA=carboplatin; L-pam=melphalan; Dex=dexametha-sone.
determine the probability of significant differences when comparing two groups. P-values o0.05 were considered significant. The Pearson's correlation coefficient was utilized for correlation statistics.
Cells and cell culture
Peripheral blood and BM cells were obtained from four healthy volunteers, and mononuclear cells were separated from these samples. BM mononuclear cells were also separated into CD34 + and CD34 À cells using an immunomagnetic bead system (MACS, Miltenyi Biotec, Glodbach, Germany). CD34
À cells were further fractionated into
À cells by sorting with a FACS Vantage TM . The CFU-C assay was performed as described previously 1 . All cultures were done in triplicate, and the number of CFU-C was scored at day 10 of culture. The colony types were determined by in situ observations using an inverted microscope.
A portion of BM mononuclear cells was cultured in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS) at 371C in a humid atmosphere with 5% CO 2 . Half of the medium was recovered from 3 to 4 days, and adherent cells were collected as stromal cells.
RT-PCR
Total RNA was extracted from each type of cell using RNeasy Mini Kit (QIAGEN, Hilden, Germany). cDNA was synthesized from total RNA (1 mg) using the SuperScript First-Strand Synthesis System for RT-PCR (GIBCO BRL, Gaithesburg, MD, USA) and subjected to PCR. A fragment of SCGF cDNA (209bp) was amplified with the following primers: forward 5 0 -GTCCTCTTTTCCCTCAA CA-3 0 ; and reverse 5 0 -TTTTGGGGGCTTTGGTGG-3 0 . The PCR conditions were as follows: denaturation at 941C for 5 min, followed by 25 cycles consisting of denaturation at 941C for 1 min, annealing at 611C for 1 min, elongation at 721C for 1 min, and final reaction at 721C for 7 min. A fragment of G3PDH cDNA (546 bp) was amplified with the primers, 5 0 -CCCATCACCATCTTCCAGGAGC-3 0 and 5 0 -TTCACCACCTTCTTGATGTCATCATA-3 0 . The PCR conditions were as follows: denaturation at 941C for 5 min, followed by 22 cycles consisting of denaturation at 941C for 1 min, annealing at 551C for 1 min, and elongation at 721C for 1 min, and final reaction at 721C for 7 min. The PCR products were analyzed on 2% agarose gels, stained with SYBR Green I Nucleic Acid Gel Stains (TaKaRa, Kyoto, Japan), and viewed under UV light.
Results
SCGF levels in normal volunteers and patients before SCT
The serum SCGF level in normal volunteers was 13. 072.6 ng/ml. (n ¼ 10), while those in patients before autologous SCT and allogeneic SCT were 19.2776.11 and 9.7576.8 ng/ml respectively. The serum SCGF level in autologous SCT patients was significantly higher than those in normal volunteers and allogeneic SCT patients (Po0.02). In autologous SCT patients, four of six patients received G-CSF within 1 month of sampling time.
SCGF levels after SCT
The serum SCGF levels gradually increased after SCT (Figure 2) . The maximum level of serum SCGF was observed during rapid granulocyte recovery and then the level decreased to the pre transplant level in autologous SCT patients (Figure 2a) . SCGF levels before and after autologous SCT were 19.2876.11 ng/ml and 36.557 15.67 ng/ml (n ¼ 6) (Po0.01) ( Table 2 ). The serum SCGF levels in allogeneic SCT patients increased until the time of granulocyte stabilization (Figure 2b ). SCGF levels before and after allogeneic SCT were 9.7676.81 and 25.01715.14 ng/ml (n ¼ 21) (Po0.001). In patients with and those without GVHD after allogeneic SCT (Figure 2c, d) , there was no difference in SCGF levels after SCT (23.23710.78 ng/ml (n ¼ 14) vs 26.84719.86 ng/ml (n ¼ 7)). Hence, the presence of GVHD did not affect the serum level of SCGF. The source of hematopoietic stem cells did not affect the serum level of SCGF after SCT either (24.65712.87 ng/ml in BMT (n ¼ 13) (Figure 2e ) vs 25.69719.84 ng/ml in PBSCT (n ¼ 8) (Figure 2f) ).
It is noteworthy that in two patients (nos. 18 and 19) serum SCGF did not increase in either phase after SCT. In these patients, engraftment was delayed. Serum SCGF was measured by ELISA on four occasions as Takatsuka et al. 13 previously described: (1) before SCT; (2) during the aplastic phase after SCT (days 1-7); (3) during the rapid granulocyte recovery phase (days 8-21 in allogeneic SCT patients and days 9-17 in autologous patients); and (4) at the time of granulocyte stabilization after discontinuation of G-CSF (days 20-40 in allogeneic SCT patients and days 15-27 in autologous patients). (a) autologous SCT patients; (b) all allogeneic SCT patients; (c) allogeneic SCT patients with GVHD; (d) allogeneic SCT patients without GVHD; (e) allogeneic BMT patients; (f) allogeneic PBSCT patients.
SCF levels during SCT
The serum SCF levels did not change significantly during the observation period in autologous or in allogeneic SCT patients (Figure 3a, b) . SCF levels after autologous SCT and allogeneic SCT were 796.07199.62 pg/ml (n ¼ 7) and 808.997264.22 pg/ml (n ¼ 16), respectively, and there was no significant difference among the two groups P40.2) ( Table 2) . Therefore, GVHD did not affect the serum level of SCF.
TPO levels during SCT
Serum TPO levels rapidly increased to the maximum value after autologous SCT, and then decreased to the pretransplant level in the stable phase (Figure 3c, d) . In autologous transplant patients, the serum TPO gradually increased and reached the maximum value in the aplastic phase. TPO levels before and after autologous SCT were 446.377179.48 pg/ml and 1603.367533.88 pg/ml (n ¼ 6) (Po0.001) ( Table 2 ). In allogeneic SCT patients, the maximum level of TPO was observed during rapid granulocyte recovery. TPO levels before and after allogeneic SCT were 715.57478.45 pg/ml and 1771.1571116.98 pg/ml (n ¼ 7) (Po0.02) ( Table 2 ).
IL-6 levels during SCT
In allogeneic SCT patients with and those without GVHD, serum IL-6 levels rapidly increased to the maximum value in aplastic phase and returned to the basal level before the recovery phase (Figure 3e, f) (n ¼ 7, 6 ). Therefore, the maximum level of IL-6 was observed before acute GVHD and there was no significant difference between the two groups (P ¼ 0.18). Since many allogeneic SCT patients had high fever and their serum CRP concentrations increased during the aplastic phase, it seems that the high serum IL-6 levels were also related to infection (r ¼ 0.69). In autologous SCT patients, serum IL-6 levels before SCT were 2.6971.93 pg/ml, whereas they increased to 15.40711.68 pg/ml during the rapidly granulocyte recovery and decreased to 5.0974.57 pg/ml at the time of granulocyte stabilization (Figure 3g ) (n ¼ 6). Serum IL-6 levels increased very slightly although four autologous SCT patients had fever and increase of serum CRP concentrations during the aplastic phase. Serum IL-6 levels in autologous SCT patients were significantly lower than those in allogeneic SCT patients (Po0.05). Therefore, not only infection but also the GVH reaction affected the serum level of IL-6.
The source of human SCGF production
In order to elucidate the types of BM cells expressing SCGF, we carried out RT-PCR analysis and a clonogenic assay using peripheral blood cells and BM cells from 4 
CD33
+ cells produced only CFU-GM, CFU-GM and CFU-M. The plating efficiency was 37.5% in CD34 + cells and 1.5% in CD34 À CD33 + cells. Therefore, the cell populations expressing SCGF in BM mononuclear cells possess the colony-forming cell abilities.
Discussion
We established a sandwich ELISA to quantify SCGF, a new growth factor of primitive hematopoietic progenitor cells. The serum level of SCGF in normal volunteers (13.072.6 ng/ml) was quite high when compared with other hematopoietic cytokines such as SCF or TPO. 14, 15 Moreover, we actually measured serum cytokines levels in patients undergoing SCT using this assay. In most patients serum SCGF levels gradually increased after SCT. Regardless of the presence of GVHD or type of transplant, SCGF levels significantly increased after SCT. Serum SCGF levels did not correlate with serum CRP levels (r ¼ 0.02), nor with granulocyte (r ¼ 0.34) or platelet count (r ¼ À0.13) in the peripheral blood. The maximum level of SCGF was observed during the rapid granulocyte recovery phase in autologous patients, and during the granulocyte stabilization phase in allogeneic SCT patients, so that serum SCGF levels began to rise earlier in autologous SCT patients than in allogeneic SCT patients. Among allogeneic patients, serum SCGF levels in PBSCT patients began to rise earlier than in BMT patients. The recovery of hematopoiesis following SCT is generally earlier in autologous patients than in allogeneic patients, and it is also earlier in PBSCT patients than in BMT patients. In this study, the median time from SCT to ANC4500, Platelets450 000 and duration of G-CSF administration were 9,10.5 and 14.5 days in autologous SCT patients, and 18, 15, 23 days in allogeneic SCT patients. These data suggested that the kinetics of serum SCGF levels are associated with the recovery of hematopoiesis following SCT, although no single parameter correlated with serum SCGF. Two other findings mentioned below support this notion. À BM mononuclear cells were sorted into three subpopulations; CD34 In autologous SCT patients, serum SCGF levels before SCT (mean 19.275 ng/ml) were significantly higher than in allogeneic SCT patients (mean 9.757 ng/ml) or normal controls (Po0.01). As four of six autologous SCT patients underwent PBSC harvest within a month before SCT, we thought that excess hematopoiesis was related to high serum SCGF levels.
Furthermore, in two patients (patients nos. 18 and 19) the serum SCGF levels did not increase during the observation period after SCT in this study and in these patients recovery of hematopoiesis was delayed, so that they depended on transfusion of platelets for more than 50 days. This suggests that in patients whose serum SCGF levels do not increase, hematopoiesis will take more time to recover following SCT.
In a previous mouse study 3 the expression of SCGF was shown to localize in BM, proliferating chondrocytes, the perichondrium and periosteum. Therefore, we further analyzed SCGF production in BM cells. TPO, SCF and IL-6 are other hematopoietic cytokines working during early hematopoesis. 16 Therefore, we measured the serum level of these cytokines together with SCGF in this study. Serum TPO levels markedly increased after SCT and gradually decreased as platelets recovered. Serum TPO levels were previously described to correlate inversely with platelet counts rather than with hematopoietic recovery. Serum SCF levels, in this study as well as other studies, 17 did not change after SCT. There was no specific association between serum SCF levels and hematopoiesis following SCT. IL-6 was described as an inflammatory cytokine and to correlate with serum level of CRP. 18 There was also a weak negative correlation of IL-6 with leukocyte or platelet counts. In this study, most patients showed elevation of serum IL-6 levels during the aplastic phase. Serum IL-6 levels in autologous SCT patients were significantly lower than those in allogeneic patients. Serum IL-6 levels indicate the presence of an inflammatory reactions, such as infection and GVHD, rather than hematopoiesis in these patients.
Although many cytokines have been reported to have a role in hematopoiesis, none of them directly reflects the status of post transplant hematopoiesis. [6] [7] [8] [9] [10] 17, 18 In this study, we demonstrate the parallel kinetics between serum SCGF levels and hematopoietic recovery after SCT. The time from SCT to the peak of serum SCGF levels differed according to the type of transplant, but after granulocyte stabilization those levels decreased in all cases. It is also suggested that in patients whose serum SCGF levels do not increase hematopoiesis will take much time to recover after SCT. The SCGF protein can be easily determined by ELISA, and the assay can be performed within several hours if a serum sample is available. Hence, SCGF can be a useful predictor of recovery of hematopoiesis following SCT.
